摘要
目的分析重组人血管内皮抑素(rh-endostatin,恩度)联合化疗治疗晚期非小细胞肺癌(NSCLC)患者的临床疗效、不良反应和对患者生活质量的影响。方法 176例晚期NSCLC患者采用随机数字表法分为试验组和对照组,试验组90例患者采用重组人血管内皮抑素加一线化疗方案,对照组86例患者仅选用一线化疗方案。化疗2个周期后评价两组患者的近期临床有效率、临床受益率以及生活质量的改善程度,同时观察不良反应。结果试验组患者的临床有效率为44.4%,临床受益率为82.2%,而对照组患者分别为32.6%和63.9%,两组有效率差异无统计学意义(χ2=2.621,P=0.105),但两组临床受益率差异有统计学意义(χ2=7.499,P=0.006)。两组患者治疗后生活质量均有所改善,实验组则更为明显,差异有统计学意义(χ2=11.381,P=0.007)。不良反应主要为血小板降低、白细胞降低和恶心呕吐等,试验组与对照组患者的不良反应发生率差异无统计学意义(P>0.007)。结论在晚期NSCLC患者的治疗中,重组人血管内皮抑素联合化疗药物疗效较好,在改善患者生活质量方面具有优势,安全性较好。
Objective To investigate the short-term efficacy,safety and the quality of life of the target therapy of rh-endostatin combined with chemotherapy in patients with advanced non-small cell lung cancer（ NSCLC）. Methods One hundred and seventy-six advanced NSCLC patients were randomly divided into trial group（ 90 cases） with chemotherapy plus rh-endostatin and control group（ 86 cases） with chemotherapy alone. The efficacy and toxicity were evaluated after 2 cycles according to Response Evaluation Criteria in Solid Tumors criteria. Results The efficacy rate of trail group was 44. 4%,while the control group was 32. 6%,there was no significant difference between two groups（ χ^2= 2. 621,P = 0. 105）. The clinical benefit rate was 82. 2% in the trail group and 63. 9% in the control group. There was significant difference of the clinical benefit rate between the trail group and the control group（ χ^2= 7. 499,P =0. 006）. The score of quality of life in the trail group was significantly higher than that in control group after the treatment（ χ^2= 11. 381,P = 0. 007）. There were no significant differences between the two groups in untoward effects including thrombocytopenia,leucopenia,nausea and vomiting. Conclusion In the treatment of patients with advanced NSCLC,the therapy of rh-endostatin combined with chemotherapy can evidently raise clinically beneficial rate and improve the quality of life,and with good safety.
出处
《中国肿瘤临床与康复》
2015年第2期185-187,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
